Document is current
Any future updates will be listed below
-
Authors
El Kodsi, Daniel N.
Tokarew, Jacqueline M.
Sengupta, Rajib
Lengacher, Nathalie A.
Chatterji, Ajanta
Nguyen, Angela P.
Boston, Heather
Jiang, Qiubo
Palmberg, Carina
Pileggi, Chantal
Holterman, Chet E.
Shutinoski, Bojan
Li, Juan
Fehr, Travis K.
LaVoie, Matthew J.
Ratan, Rajiv R.
Shaw, Gary S.
Takanashi, Masashi
Hattori, Nobutaka
Kennedy, Christopher R.
Harper, Mary-Ellen
Holmgren, Arne
Tomlinson, Julianna J.
Schlossmacher, Michael G. https://orcid.org/0000-0002-0394-0300
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (FDN143278, PJT- 452990, PJT-166019)
Michael J. Fox Foundation for Parkinson's Research
National Institutes of Health (R01NS065013)
Uttra and Sam Bhargava Family
Department of Medicine at The Ottawa Hospital and Faculty of Medicine
- License Information
-
More Information
Article History
Received: 30 November 2022
Accepted: 1 December 2022
First Online: 23 January 2023
Declarations
:
: The Ottawa Hospital receives payments from BioLegend Inc. related to licensing agreements for immunological reagents related to parkin and α-synuclein. Dr. M. Schlossmacher received travel reimbursements from the Michael J. Fox Foundation for Parkinson’s Research for participation in industry summits and consulting fees (Biogen; Neuramedy; Samsara) as well as royalties from Eli Lilly for patents unrelated to this work. Dr. A. Holmgren (deceased) served as chairman and senior scientist at IMCO Corporation Ltd AB, Stockholm, Sweden. No additional, potentially competing financial interests are declared.
